[[Biora Therapeutics|Biora Therapeutics]] reports that existing shareholders may be diluted by future sales and issuances of common stock. > [!quote] Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause the stock price of our common stock to decline. > > In the future, we may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. We also expect to issue common stock to employees, directors, and consultants pursuant to our equity incentive plans. If we sell common stock, convertible securities, or other equity securities in subsequent transactions, or common stock is issued pursuant to equity incentive plans, investors may be materially diluted. New investors in such subsequent transactions could gain rights, preferences, and privileges senior to those of holders of our common stock. > > Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause the price of our common stock to decline. > > Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. > > Source: [10-Q (2022-05-10)](https://www.sec.gov/Archives/edgar/data/0001580063/000095017022009028/bior-20220331.htm)